Literature DB >> 16264826

Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.

W Nicol Keith1, Alan Bilsland, Maryon Hardie, T R Jeffry Evans.   

Abstract

Rapid advances in our understanding of the molecular basis of cancer development and progression over the past three decades have led to the design of new potential cancer therapies. High throughput target validation and expression studies are expected to yield a powerful arsenal of new cancer treatments, but untangling the complex pathways underlying the major cancer phenotypes remains a significant challenge. A considerable body of evidence in recent years implicates deregulated expression of a single multi-component enzyme, telomerase, as a causative factor at the heart of immortalization in the vast majority of human tumors. This review highlights the potential of telomerase as a target for novel cancer therapies. The potential of exploiting the selectivity of the telomerase family of genes within cancer cells to develop gene therapy strategies is discussed, and the progress towards translating these novel therapeutics from the laboratory to the clinic is reviewed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16264826     DOI: 10.1038/ncponc0044

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  9 in total

Review 1.  Gene therapy in head and neck cancer: a review.

Authors:  E Chisholm; U Bapat; C Chisholm; G Alusi; G Vassaux
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

Review 2.  Virotherapy: cancer gene therapy at last?

Authors:  Alan E Bilsland; Pavlina Spiliopoulou; T R Jeffry Evans
Journal:  F1000Res       Date:  2016-08-30

3.  Properties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.

Authors:  Alan E Bilsland; Aileen Fletcher-Monaghan; W Nicol Keith
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

4.  Dynamic telomerase gene suppression via network effects of GSK3 inhibition.

Authors:  Alan E Bilsland; Stacey Hoare; Katrina Stevenson; Jane Plumb; Natividad Gomez-Roman; Claire Cairney; Sharon Burns; Kyle Lafferty-Whyte; Jon Roffey; Tim Hammonds; W Nicol Keith
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

5.  Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer.

Authors:  C-Q Zhu; J-C Cutz; N Liu; D Lau; F A Shepherd; J A Squire; M-S Tsao
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

Review 6.  Therapeutic targeting of replicative immortality.

Authors:  Paul Yaswen; Karen L MacKenzie; W Nicol Keith; Patricia Hentosh; Francis Rodier; Jiyue Zhu; Gary L Firestone; Ander Matheu; Amancio Carnero; Alan Bilsland; Tabetha Sundin; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang
Journal:  Semin Cancer Biol       Date:  2015-04-11       Impact factor: 15.707

7.  Loss of Cyclin-Dependent Kinase Inhibitor Alters Oncolytic Adenovirus Replication and Promotes More Efficient Virus Production.

Authors:  Naseruddin Höti; Tamara Jane Johnson; Wasim H Chowdhury; Ronald Rodriguez
Journal:  Cancers (Basel)       Date:  2018-06-15       Impact factor: 6.639

Review 8.  Targeting telomerase for cancer therapeutics.

Authors:  J W Shay; W N Keith
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

Review 9.  Therapeutic Targeting of Telomerase.

Authors:  Kathrin Jäger; Michael Walter
Journal:  Genes (Basel)       Date:  2016-07-21       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.